Search results for "Highlights"
Natriuretic peptide levels predicted heart failure risk in diabetes
A test manufacturer's retrospective analysis of type 1 and 2 diabetes patients who underwent natriuretic peptide testing found that elevated levels of terminal pro-brain natriuretic peptide or B-type natriuretic peptide were associated with development of heart failure and death.
https://diabetes.acponline.org/archives/2025/11/14/3.htm
14 Nov 2025
Physical activity may help address hyperglycemia in type 1 diabetes
Exercise bouts of 10 to 30 minutes led to a mean change of −2.2 mmol/L (−39.6 mg/dL) in glucose level compared with no activity in patients with type 1 diabetes, a study found.
https://diabetes.acponline.org/archives/2025/11/14/2.htm
14 Nov 2025
Hyperglycemia common, linked with poor outcomes in general surgery patients
More than 6% of 282,131 general surgery patients had HbA1c levels in the diabetic range but did not have a diabetes diagnosis, an analysis of a U.S. database found.
https://diabetes.acponline.org/archives/2025/11/14/1.htm
14 Nov 2025
Role of weight loss in prediabetes remission examined
Whether patients had remission of prediabetes in response to an intensive lifestyle intervention was not determined by whether they lost weight, a post hoc analysis of a trial in Germany found. Those who achieved remission did have different distribution of their adipose tissue, however.
https://diabetes.acponline.org/archives/2025/10/10/3.htm
10 Oct 2025
Overuse of HbA1c testing may be common in nursing home residents with diabetes
HbA1c levels were tested frequently even in patients not taking medications for their diabetes, those taking medications with low risk for hypoglycemia, and those whose HbA1c levels were in the target range, a Canadian study found.
https://diabetes.acponline.org/archives/2025/10/10/2.htm
10 Oct 2025
Semaglutide discontinuation more common in patients with diabetes plus stroke, CKD
A study of older adults with diabetes who initiated a glucagon-like peptide-1 receptor agonist found that, in the U.S., more than half had discontinued it within a year, with higher discontinuation rates among those with chronic kidney disease (CKD), a history of stroke, or peripheral vascular disease.
https://diabetes.acponline.org/archives/2025/10/10/1.htm
10 Oct 2025
Statins provided primary prevention benefit in younger patients with type 1 diabetes
Researchers used a British database to conduct a target-trial emulation assessing the benefits of statin initiation in type 1 diabetes patients with a mean age of 45 years. They found significant decreases in 10-year risk of all-cause mortality and cardiovascular disease in those who took statins.
https://diabetes.acponline.org/archives/2025/09/12/3.htm
12 Sep 2025
Semaglutide, tirzepatide showed improved outcomes in patients with HF and diabetes
Risk for heart failure (HF) hospitalization or all-cause mortality was more than 40% lower in patients with type 2 diabetes and HF with preserved ejection fraction who took semaglutide or tirzepatide compared to those who took sitagliptin (a placebo proxy), a study found.
https://diabetes.acponline.org/archives/2025/09/12/2.htm
12 Sep 2025
New living guideline offers advice on medications for type 2 diabetes
The risk-stratified recommendations, developed by an international panel for the BMJ Rapid Recommendations series, are intended to help physicians and patients choose among sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, finerenone, and tirzepatide.
https://diabetes.acponline.org/archives/2025/09/12/1.htm
12 Sep 2025
Mixed findings on associations between tirzepatide and diabetic retinopathy
New-onset proliferative diabetic retinopathy occurred in 1.1% of patients on tirzepatide versus 0.5% of matched controls, but new onset of any retinopathy was less common in patients with diabetes who took tirzepatide and had no retinopathy at baseline, a retrospective study found.
https://diabetes.acponline.org/archives/2025/08/08/3.htm
8 Aug 2025
Type 2 diabetes remission more likely in patients taking fewer medications, study finds
Just 2.9% of more than 556,000 type 2 diabetes patients who did not undergo bariatric surgery achieved remission over three years, and 36.9% of them relapsed before the end of the three-year follow-up, according to analysis of data from six U.S. health systems.
https://diabetes.acponline.org/archives/2025/08/08/2.htm
8 Aug 2025
Guidance offered on handling pregnancy in patients with pre-existing diabetes
A new joint clinical practice guideline from the Endocrine Society and the European Society of Endocrinology suggests screening for pregnancy intent in diabetes patients and addresses use of glucagon-like peptide-1 receptor agonists, insulin, and continuous glucose monitoring before and during pregnancy.
https://diabetes.acponline.org/archives/2025/08/08/1.htm
8 Aug 2025
Fenofibrate cost-effective for preventing diabetic retinopathy progression
In diabetes patients with mild background retinopathy in both eyes or observable background retinopathy or maculopathy in one or both eyes, treatment with fenofibrate reduced the need for any referable diabetic retinopathy or treatment by 4.4% over two years, an analysis of a randomized trial found.
https://diabetes.acponline.org/archives/2025/07/11/3.htm
11 Jul 2025
Mifepristone improved diabetes control in hypercortisolism, industry trial finds
Patients with poorly controlled type 2 diabetes and hypercortisolism assigned to mifepristone versus placebo had lower HbA1c levels and greater reductions in body mass index and waist circumference at 24 weeks, although adverse events were common.
https://diabetes.acponline.org/archives/2025/07/11/2.htm
11 Jul 2025
Semaglutide associated with lower stroke risk than empagliflozin
An analysis of observational data found better outcomes with semaglutide than empagliflozin, particularly in patients younger than age 65 years. Outcomes with dulaglutide were similar to those with empagliflozin.
https://diabetes.acponline.org/archives/2025/07/11/1.htm
11 Jul 2025
Diabetes progression linked with increased risk of kidney cancer
Kidney cancer risk was significantly higher in patients with prolonged duration of diabetes, those with diabetic retinopathy or nephropathy, and those with poor glycemic control, a cohort study in South Korea found.
https://diabetes.acponline.org/archives/2025/06/13/3.htm
13 Jun 2025
Renal outcomes better with finerenone plus empagliflozin in type 2 diabetes and CKD
Patients with type 2 diabetes and chronic kidney disease (CKD) had a greater reduction in urinary albumin-to-creatinine ratio if they took finerenone plus empagliflozin versus either drug alone, an industry trial found.
https://diabetes.acponline.org/archives/2025/06/13/2.htm
13 Jun 2025
ADA consensus report calls for MASLD, liver fibrosis screening in type 2 diabetes
A two-tier system for stratifying patients based on their risk of metabolic dysfunction-associated steatotic liver disease (MASLD) was recommended by the American Diabetes Association (ADA).
https://diabetes.acponline.org/archives/2025/06/13/1.htm
13 Jun 2025
Studies examine prescribing patterns, access issues with newer diabetes drug classes
Use of tirzepatide, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors increased sharply in the U.S. from 2021 to 2023, one study found, while another noted inequities in availability of newer medications for type 2 diabetes.
https://diabetes.acponline.org/archives/2025/05/09/3.htm
9 May 2025
Standard care noninferior to acellular, cellular matrix products for diabetic foot ulcers
Researchers found no clinically significant differences in ulcer healing between the treatment types but found that acellular matrix products were more cost-effective than cellular matrix products and should thus be considered if standard care fails.
https://diabetes.acponline.org/archives/2025/05/09/2.htm
9 May 2025